Clinical and radiological disease reactivation after cessation of long-term therapy with Natalizumab

Annette Baumgartner*, Oliver Stich, Sebastian Rauer

*Corresponding author for this work
15 Citations (Scopus)


Naitalizumab is a potent monoclonal antibody approved for the treatment of relapsingremitting multiple sclerosis (MS); however, little is known about the course of disease after cessation of therapy. The few existing reports describe different courses of disease after treatment discontinuation. Here we report on four MS patients who experienced clear clinical and radiological reactivation of the disease several months after cessation of therapy with natalizumab (1529 months). In all cases, there was almost no clinical or radiological disease activity during natalizumab therapy. Three patients experienced a severe clinical relapse between 3 and 9 months after therapy cessation. The fourth patient developed cerebral magnetic resonance imaging (MRI) activity showing multiple new gadolinium-enhanced lesions. Due to these observations, it is recommended to weigh up the risk of disease reactivation against the risk of progressive multifocal leukoencephalopathy.

Original languageEnglish
JournalInternational Journal of Neuroscience
Issue number1
Pages (from-to)35-39
Number of pages5
Publication statusPublished - 01.2012

Research Areas and Centers

  • Health Sciences

DFG Research Classification Scheme

  • 206-06 Molecular and Cellular Neurology and Neuropathology
  • 206-02 Molecular Biology and Physiology of Nerve and Glial Cells

Cite this